Identifying predictive proteomic biomarkers of selective serotonin reuptake inhibitor treatment effect in depression.

Key Points

• To identify biomarkers that predict the response to SSRI treatment in major depressive disorder (MDD).
• Analysis of proteomic data to identify potential biomarkers.
• Examination of SHBG for its predictive value in treatment response.
• Exploration of molecular mechanisms involving sex-hormone and immune-inflammatory pathways.
• SHBG is identified as a potential biomarker for predicting SSRI treatment response.
• The interplay between sex-hormones and immune pathways is highlighted as significant in MDD.
• Insights into molecular mechanisms of SSRI therapy are elaborated.